BenchSci

BenchSci's EMET unifies data, models, skills, and lab-in-the-loop into one agentic research environment for preclinical R&D.

EMET helps discovery teams validate targets, map disease biology, and interpret multi-omics evidence to reach decision-ready answers.

EMET assists preclinical teams in designing experiments, profiling compounds, analyzing CRISPR screens, and triaging PK/PD data using AI evidence workflows.

EMET supports discovery, preclinical, translational, clinical, medical affairs, and regulatory teams with AI-powered evidence workflows.

Dr. Vijyendra Ramesh works at the Dana-Farber Cancer Institute, studying kidney cancer through bench research and computational analysis.

Recent updates, documentation improvements, and platform changelogs.

EMET integrates with internal documents, electronic lab notebooks, reports, and experimental databases, connecting them to public and paywalled evidence.

Kyle Medak researches the effects of GLP-1 receptor agonists in the kidney, building on findings from a completed clinical trial.

Scientist-led competitive selection deepens BenchSci's presence in European biopharma

Integration of diverse scientific journals enhances the ASCEND platform, benefiting researchers across key therapeutic areas.

BenchSci lists career opportunities, company values, perks, and open roles.

Two ways to use BenchSci: free academic access and a tailored enterprise plan with full data, custom integrations, and dedicated support.

The page compares BenchSci and Causaly as AI platforms for drug discovery preclinical research, noting scattered data sources and models.

Biopharma has long used AI, but recent advancements in agentic AI shift focus from adoption to implementation in scientific reasoning.

A new type of AI in drug discovery uses autonomous agents to analyze literature, perform analyses, and propose experiments independently.

AI in preclinical research previously involved narrow models for specific tasks, such as structure prediction or literature classification.

BenchSci began with a failed experiment and details its origin story, mission, leadership, and investors.

Prototype of the BenchSci 2026 marketing site. Built with Next.js, Tailwind, and (optionally) Three.js + Claude Skills.

BenchSci provides contact information, including a demo request option and office address at 559 College St., Toronto.

Users can apply for access to EMET by submitting information for review by the BenchSci team.

Find answers, integration guides, and platform updates.

EMET is an agentic research environment for preclinical R&D, reasoning across 38 million publications and a curated knowledge graph beyond simple search.

BenchSci Privacy Notice explains how the company collects, uses, shares, and protects personal information.

BenchSci Ethics and Compliance Hotline — confidential reporting for concerns.

BenchSci Terms of Service govern the use of its platform and services.

BenchSci outlines its accessibility policy and multi-year plan.

BenchSci integrates Patsnap’s patent data into its EMET platform, enabling preclinical scientists to assess patent and clinical status of drug targets within a unified research workflow. The partnership combines patent intelligence with drug development tools to streamline scientific decision-making.

Oct 2026benchsci.comNews article

Emet identifies two untested drug combinations for a cancer lacking known druggable targets. Early lab tests validate both hypotheses, suggesting a new approach to targeting previously undruggable cancers.

Sep 2026benchsci.comNews article

BenchSci secures a two-year enterprise deal with **argenx** to integrate AI tools into preclinical drug discovery. The agreement follows a scientist-led selection process, expanding BenchSci’s footprint in European biopharma. Both companies aim to accelerate early-stage research through data-driven insights.

Sep 2026BioSpaceNews article

BenchSci integrates its **EMET agentic research environment** onto **Google Cloud**, positioning itself as a critical provider of AI-driven scientific reasoning and automation tools for biology research. The partnership aims to address gaps in infrastructure by leveraging cloud-based scalability for data-intensive workflows. BenchSci’s platform now operates primarily on Google Cloud, enhancing accessibility for researchers.

Aug 2026benchsci.comNews article